Supplementary Figure 14

Case 1, tAML

Case 2, Blood

Case 3, Kidney

Case 3, Liver

Case 3, Pancreas

Case 3, Lung

Case 3, Spleen

Case 3, Bone Marrow

Supplementary Figure 14. Calculation of confidence intervals of activity of SBS31.
We built one synthetic sample with the contributions of different signatures (excluding SBS31/35) fitted for every normal tissue (or tumor). Then, an increasing number of platinum mutations (i.e., following the tri-nucleotide probabilities of SBS31) were injected into these samples, and after every injection, the exposure to SBS31 and aging mutational processes (SBS1+SBS5+SBS40) were computed 100 times using mSigAct. Then, by intersecting the obtained distributions with horizontal lines set at the positions corresponding to the observed exposure of platinum and age-related mutations provided confidence intervals to these values. (See details in Methods.)
Case 1 tAML; Case 2 blood sample; Case 3 kidney, liver, pancreas, lung, spleen and bone marrow samples; Unrelated non-treated donor 1 and 2 blood samples.